SCHEMBL11945256

SCHEMBL11945256

COC(=O)c1ccc(CS(=O)(=O)N2CCN(c3cnn(-c4cc(F)cc(F)c4)c(=O)c3OC3CCCC3)CC2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.38
▸ LMNA P02545 1/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ GAA P10253 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NCOA3 Q9Y6Q9 1/20 0.34
▸ NPBWR1 P48145 2/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ HRH1 P35367 1/20 0.34
▸ USP7 Q93009 1/20 0.34
▸ PDE4A P27815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11945172 0.93 MAPT (0.42) MAPTLMNANPSR1ALDH1A1HSD17B10
SCHEMBL11944017 0.92 MAPT (0.41) MAPTLMNANPSR1ALDH1A1HSD17B10
SCHEMBL11945166 0.88 MAPT (0.45) MAPTLMNANPSR1ALDH1A1HPGD
SCHEMBL11944488 0.88 MAPT (0.39) MAPTLMNANPSR1ALDH1A1MAPK1
SCHEMBL11945123 0.88 MAPT (0.44) MAPTLMNANPSR1ALDH1A1HPGD
SCHEMBL11944040 0.87 MAPT (0.40) MAPTLMNANPSR1ALDH1A1MAPK1
SCHEMBL11946394 0.86 MAPT (0.44) MAPTLMNANPSR1ALDH1A1HPGD
SCHEMBL11945144 0.86 MAPT (0.39) MAPTLMNANPSR1ALDH1A1MAPK1
SCHEMBL11945356 0.86 MAPT (0.39) MAPTLMNANPSR1ALDH1A1MAPK1
SCHEMBL11944776 0.86 MAPT (0.40) MAPTLMNANPSR1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885LMNA 929/4885NPSR1 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback